Severe Hypertriglyceridemia (SHTG) Treatment Market (2025 - 2035)

Severe Hypertriglyceridemia (SHTG) Treatment Market Analysis – Size, Share, and Forecast 2025 to 2035

The severe hypertriglyceridemia (SHTG) treatment industry is valued at USD 950 million in 2025. As per FMI's analysis, the market will grow at a CAGR of 14.3% and reach USD 3.61 billion by 2035.

The treatment market for severe hypertriglyceridemia (SHTG) saw significant growth in 2024, fuelled by regulatory clearances, increased patient access, and growing clinical trial activity.

According to research by FMI, big drug companies sped up late-stage clinical trials for new triglyceride-lowering drugs, and some of them were given FDA fast-track designations. Reimbursement systems in North America and Europe were also strengthened, enhancing the accessibility of treatments.

FMI thinks that the acceptance of RNA-based treatments sped up because a number of biotech companies entered the SHTG Treatment market. Continued innovation in gene-based therapeutics and combination lipid-lowering therapies will fuel industry expansion through 2025 and in the future years.

FMI research predicts a surge in demand in Asia-Pacific markets due to the increasing incidence of metabolic disorders and healthcare spending. Competition will also increase as entrants bring with them cost-competitive substitutes.

Industry Forecast Table

Metric	Value
Industry Size (2025E)	USD 950 Million
Industry Value (2035F)	USD 3.61 Billion
CAGR (2025 to 2035)	14.3%

Key Success Factors Driving the SHTG Treatment Industry

The market for treating severe hypertriglyceridemia (SHTG) is growing quickly. This is because the disease is becoming more common, drug approvals are being sped up, and new RNA-based and gene-targeted therapies are being developed.

According to the FMI study, pharmaceutical companies that come up with new lipid-lowering therapies will benefit the most. Conversely, generic drug companies will face significant challenges in competing in a market increasingly dominated by high-efficacy biologics. According to FMI, the industry will continue to grow until 2035 because more investments will be made in healthcare in emerging markets and reimbursement policies will be made stricter.

Top 3 Strategic Imperatives for Stakeholders

Drive innovation in RNA- and gene-based therapies.

Executive leaders must lead investments in innovative lipid-lowering therapies, RNA-based, and gene-editing technologies to secure a competitive advantage and address the mounting demand for highly effective solutions.

Consolidate Market Access and Reimbursement Strategies

The adoption and enhancement of patient access to high-end SHTG Treatment will be fuelled by changing healthcare policies and increasing reimbursement coverage in priority geographies, particularly North America and Asia-Pacific.

Establish Strategic Partnerships and M&A for Competitive Advantage

The pharmaceutical and biotechnology industries need to make strategic partnerships, license agreements, and acquisitions to stay ahead of the competition for a long time. This will help them do better research and development (R&D), speed up their clinical pipelines, and strengthen their presence in markets with a lot of growth.

Top 3 Risks Stakeholders Should Monitor

Risk	Probability & Impact
Regulatory Delays in Drug Approvals	High Probability-High Impact
Pricing Pressures and Reimbursement Challenges	Medium Probability-High Impact
Competition from Cost-Effective Generics	High Probability-Medium Impact

1-Year Executive Watch-list

Priority	Immediate Action
Expansion of RNA-Based Therapies	Accelerate clinical trials and secure regulatory fast-track designations
Market Access Optimization	Strengthen payer negotiations and expand reimbursement frameworks in key regions
Competitive Positioning	Pursue strategic M&A or licensing deals to enhance pipeline and global footprint

For the Boardroom

To stay ahead of the competition, businesses need to quickly invest in RNA-based and gene-targeted therapies and get fast-track approvals from regulators. FMI Research highlights that optimising reimbursement strategies and strengthening market access will be critical for long-term adoption in high-growth regions. FMI believes that strategic M&A and licensing deals should be prioritised to expand therapeutic pipelines and establish dominance in an increasingly competitive landscape shift towards high-efficacy biologics.

FMI Survey on Severe Hypertriglyceridemia Treatment Industry:

Key Priorities of Stakeholders

Global Consensus

• Efficacy & Safety: 87% of stakeholders identified clinical efficacy and long-term safety as the primary factors influencing decisions regarding SHTG Treatment.
• Affordability and Reimbursement: 79% of those who answered were worried about the need for more insurance coverage and treatment options that don't cost too much.

Regional Variance

• In North America, 65% said that quick regulatory approvals (like FDA fast-track designations) were very important for business success.
• Europe: 81% noted the evolving need to comply with emerging EU platelet-lowering treatment guidelines.
• Asia-Pacific: 58% cited increased demand for low-cost generic alternatives amid higher healthcare costs.

Adoption of Emerging Therapies

Innovation Leaders

• In North America, 54% of healthcare providers have early adopters of RNA-based therapies. This is because of progress made in clinical trials.
• Europe: 49% recommended combination lipid-lowering regimens to improve patient outcomes with stringent reimbursement criteria.
• In the Asia-Pacific region, 33% were not sure about expensive biologics because they thought they might not be able to afford them and because approvals were taking too long.

Diverging ROI Perspectives

72% of stakeholders in North America think that new treatments should be more expensive because they work better, but only 39% of stakeholders in Asia agree. They prefer models that are based on affordability.

Sensitivities on Pricing & Reimbursement

Global Concerns

• Nine out of ten payers said that rising costs were the biggest problem in the industry, and pricing models for drugs are getting more attention.
• 67% of pharmaceutical executives said they would be moving towards value-based pricing to meet import duties from payers.

Regional Differences

• North America: Among insurers, 58% favour outcomes-based reimbursement models with high-cost therapies.
• Europe: Percentage supporting government-negotiated pricing mechanisms for controlling spending on SHTG drugs: 71%
• Asia-Pacific: 64% preferred lower-cost generic alternatives, while just 22% favoured premium-priced biologics.

Regulatory and policy impacts

Policy-Driven Market Shifts

• In the USA, 69% of manufacturers said that changing the way FDA approvals work was a big part of how long it took to launch their products.
• In Europe, 76% of people said that stricter guidelines for managing lipid disorders would make people more likely to use new therapies.
• In the Asia-Pacific region, 41% of stakeholders said that regulatory hurdles made it harder for patients to get advanced therapies.

Reimbursement Bottlenecks

• 82% of stakeholders in Europe had to go through long negotiations on market access because of thorough cost-benefit analyses.
• 57% of healthcare providers in North America said that private insurers didn't always cover new SHTG Treatment the same way.

Future Investment Priorities

Industry Alignment

73% of pharmaceutical manufacturers aim to invest in next-generation RNA-based and gene therapies.

Regional Priorities

• In North America, 62% of research and development efforts are focused on improving biologics.
• Europe: 58% invest in combination therapies that target various lipid pathways.
• Asia-Pacific: 46% are focused on cost-effective manufacturing and distribution models.

Market players and entry barriers

Pharmaceutical Manufacturers

• In the United States, 51% reported challenges in scaling up manufacturing due to the complex production of biologics.
• Europe: 48% said regulatory compliance costs have risen.
• Asia-Pacific: 55% had domestic generic drugmakers competing on price.

Health Care Professionals & End Users

• North America: 43% cited lack of physician education on new treatments.
• Europe: 41% faced treatment access disparities between public and private healthcare systems.
• In Asia-Pacific, 59% of treatment uptake was limited due to affordability concerns.

Regional Disparities in the Consensus of the Industry

Global Agreement

Industrywide, high efficacy, affordability, and regulatory clarity continue to be priorities.

Key Variances

• North America: Bureau of Innovation (early adopter of premium biologics)
• Europe: The government has a strong influence on pricing and reimbursement policies.
• Asia-Pac: Demand for pocket-friendly solutions vs. costly novel therapies.

Strategic Insight

There is no universally effective approach to commercialisation. They are trained on how to adapt product positioning, pricing, and market access strategies to each region’s problematic access points, which have unique affordability constraints, regulatory domains, and treatment preference ecosystems.

Government Regulations

Country	Regulatory Impact & Mandatory Certifications
United States	Biologics License Applications (BLA) and New Drug Applications (NDA) are the two ways that the FDA controls SHTG Treatment. The new polar priority tests prioritise fast-track and breakthrough therapy designations for novel lipid- designation medicines. The medical transparency law's new rules on prices and Medicare's ability to negotiate drug prices are both putting more pressure on prices.
United Kingdom	After Brexit, the drugs regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), will only have a slimmer regulatory alignment with the EU for authorisation. The National Institute for Health and Care Excellence (NICE) wants detailed cost-effectiveness analyses, so getting approval for reimbursement ahead of time can make it harder to get into the market.
France	The French National Agency for Medicines and Health Products Safety (ANSM) requires very strict approvals for clinical trials. The Economical Committee for Health Products (CESP) is in charge of reimbursement, and the Haute Autorité de Santé (HAS) does pharmacoeconomic analyses. This system makes it take longer for people to get expensive medicines.
Germany	The BfArM demands strict clinical evidence for innovative therapies. AMNOG: The Act to Restructure the Pharmaceutical Market requires cost-effectiveness analyses after the drug has been on the market. This is usually done with price cuts within 12 months of launch.
Italy	AIFA, the Italian Medicines Agency that oversees the drug market, strictly controls drug pricing and reimbursement. Therapeutic positioning reports (RPTs) lead market access, subjecting biologics' prices to intense scrutiny. The approval process presents obstacles for new SHTG treatments.
South Korea	The revised Drug Approval System is used by the Ministry of Food and Drug Safety (MFDS) to oversee SHTG treatments. HIRA plays a significant role in determining the reimbursement of a drug, favouring affordable generics over costly biologics.
Japan	Medicines and Medical Devices Agency (PMDA) and the Ministry of Health, Labour, and Welfare (MHLW) are in charge of giving approvals. The National Health Insurance (NHI) price list sets prices, and drugs with high prices find it hard to stay profitable in the long term when prices keep going down.
China	National Medical Products Administration (NMPA) simplifies approval of new treatments via priority review channels. China's National Reimbursement Drug List (NRDL) requires market access, but price negotiation can lead to margin depletion.
Australia & New Zealand	The Therapeutic Goods Administration (TGA) and Medsafe NZ conduct stringent evidence-based assessments to approve drugs. Globally, medication reimbursement is decided by agencies such as the Pharmaceutical Benefits Scheme (PBS) in Australia and Pharmac in New Zealand, which make their recommendations on the basis of cost-effectiveness.
India	Approvals from the Central Drug Standard Control Organisation (CDSCO) govern it, and these standards are becoming more and more similar to global ones. The National Pharmaceutical Pricing Authority (NPPA) sets price caps on essential drugs that make it harder for people to use high-end biologics.

Country-Wise Analysis

United States

The United States market for the treatment of severe hypertriglyceridemia is projected to grow at a CAGR of 15.1% during 2025 to 2035. Robust R&D activity, early uptake of new lipid-lowering therapies, and a sophisticated healthcare infrastructure support the nation as the leading market.

The FDA fast-track and breakthrough therapy designations help new drugs get approved more quickly, which makes it easier for new products to hit the market.

But the Inflation Reduction Act and Medicare drug price negotiations are exerting downward pressure on drug prices. Regardless of that, the USA dominates the use of RNA-based treatments and biologics due to high healthcare spending and favourable reimbursement policies.

United Kingdom

Projections indicate that the market for treating severe hypertriglyceridemia in the United Kingdom will grow at a CAGR of 11.4% between 2025 and 2035. Although the post-Brexit regulatory reforms have streamlined the MHRA approval process, NICE appraisals, which apply strict cost-effectiveness checks, still dominate the market.

Demand for combined therapy is increasing, particularly among elderly patients, but high drug prices are a limiting factor. Government-sponsored research programmes and the growing recognition of lipid disorders support the UK market. Reimbursement approval from the NHS, however, is key to entering the market.

France

Between 2025 and 2035, the market for treating severe hypertriglyceridemia is expected to grow at a rate of 9.8% CAGR in France. Because ANSM and HAS regulations are out there, strict clinical trials and price negotiations must happen before a drug is approved.

France boasts a well-developed universal healthcare system, but the CEPS price controls render high-end biologics challenging to market. In spite of this, demand for new SHTG Treatment is on the rise with the growth in obesity and cardiovascular disease incidence. Pharmaceutical companies need to balance strict cost-effectiveness measures with the pursuit of advantageous reimbursement agreements to thrive in this market.

Germany

From 2025 to 2035, the market for treating severe hypertriglyceridemia is expected to grow at a rate of 10.2% per year in Germany. One of the most organised pharmaceutical markets in Europe, Germany's market is controlled by BfArM and AMNOG price reforms.

Cost-benefit analyses are mandatory for new therapies, often leading to price reductions in the first year. The country’s focus on precision medicine and lipid management is fuelling demand for RNA-based therapies and biologics.

To get their treatments covered by the public health insurance system (GKV), which covers more than 85% of the population, companies must make sure that their treatments meet AMNOG's cost-effectiveness assessments.

Italy

Between 2025 and 2035, the market for treating severe hypertriglyceridemia in Italy is expected to grow at a rate of 8.9% per year. The AIFA has strict rules about drug prices and reimbursement, which makes it hard for expensive therapies to break into the market. Even though everyone in Italy is covered by the public system, new therapies aren't used as quickly as they could be because of long regulatory approval delays and price caps put in place by the government.

Still, more people are becoming aware of lipid disorders and efforts to prevent heart disease are increasing the need for affordable treatments that lower lipids. To gain momentum, companies have to emphasise price negotiations and value-based reimbursement schemes.

South Korea

The market for treating severe hypertriglyceridemia in South Korea is expected to grow at a CAGR of 12.7% from 2025 to 2035. The MFDS regulatory system and the HIRA reimbursement system in South Korea have big effects on keeping drug prices low and making sure everyone can get them.

Prices are tightly controlled, but the country is investing more and more in biopharmaceutical innovation and precision medicine. Demand for advanced lipid-lowering therapies is growing because more people are becoming aware of metabolic disorders and more people are getting them. However, companies must navigate complex reimbursement negotiations because HIRA favours generics over high-cost biologics, making cost-effective formulations and domestic partnerships essential for market entry.

Japan

From 2025 to 2035, projections indicate a CAGR of 9.5% for the treatment market for severe hypertriglyceridemia in Japan. The PMDA and MHLW regulate approvals, while the NHI pricing system determines drug prices. While there is a high affinity for evidence-based medicine in Japan, expensive biologics are subject to periodic price reductions under the system for reviewing drug prices every two years.

Notwithstanding this, the growing incidence of metabolic diseases and government programs to mitigate cardiovascular risk are creating increasing demand for new treatments. Japan-focused companies need to maximise their pricing approaches and partner with local pharmaceutical companies to cope with the convoluted reimbursement process.

China

The projections indicate that the severe hypertriglyceridemia treatment market in China will grow at a CAGR of 14.6% from 2025 to 2035. The NMPA's sped-up approval processes in the country have made it easier for people to get new treatments that lower lipids, but premium biologics are still having trouble with pricing negotiations in the NRDL. China has the most people with hypertriglyceridemia in the world, so there is a lot of room for growth, especially for cheaper formulations.

Greater government spending on local pharmaceutical research and development and increased private health expenditures are fuelling demand. Foreign drug companies have to ally with domestic companies to overcome regulatory hurdles and widen distribution networks, though.

Australia & New Zealand

In Australia and New Zealand, the treatment market for severe hypertriglyceridemia is projected to grow at a CAGR of 10.8% during 2025 to 2035. The TGA and Medsafe NZ decide which drugs can be sold, while PBS (Australia) and Pharmac (NZ) decide how much drugs cost and who pays for them. These organisations are cost-conscious, preferring generics and low-cost formulations over high-priced biologics.

Yet, rising cardiovascular disease incidence and a growing government emphasis on preventive care are fuelling demand for sophisticated SHTG treatments. To get into the market, companies have to work within strict reimbursement structures and show proof of their effectiveness in the real world.

India

The treatment market for severe hypertriglyceridemia in India is forecast to grow at a CAGR of 13.2% from 2025 to 2035. CDSCO governs drug approvals, while NPPA oversees drug pricing, implementing an effective cost-containment strategy.

Even though price is very important, there is a lot of demand for cheap lipid-lowering drugs because India's middle-class population is growing and metabolic disorders are becoming more common. Generic drugs dominate the market, but health awareness is fuelling interest in new biologics and RNA therapies. Companies need to ride cost-effective models of production and price strategies to succeed in the Indian market.

Segment-Wise Analysis

By Drug Class

When it comes to treating severe hypertriglyceridemia (SHTG), olezarsen is the market leader because it works so well at lowering triglyceride levels through RNA-based mechanisms. Since tests are still going on and approvals from regulators are expected, we think Olezarsen will grow at a CAGR of 16.2% from 2025 to 2035.

Pegozafermin, which is another FGF21 analogue, is also becoming more popular, especially among people with metabolic syndrome. This is a sign of a high-growth market. Pegozafermin is anticipated to grow at a CAGR of 14.8% during the period under forecast. Epeleuton, a sophisticated fatty acid-based treatment, is emerging as a viable alternative for non-invasive patients, with its market projected to grow at a CAGR of 13.5%.

However, Lomitapide, a proven therapy, is facing side effects and competition from newer therapies, limiting its growth to a CAGR of 9.4%. Lomitapide is still very important for high-risk patients who don't get better with newer treatments.

By Drug Delivery Method

At the moment, injectables are the most popular way to treat severe hypertriglyceridemia because biologics and RNA-based medicines, like Olezarsen and Pegozafermin, need to be given under the skin. Physician-supervised drug delivery and precision-based therapies are driving expansion in this segment.

The injectable route will grow at a CAGR of 15.7% in 2025 to 2035. On the other hand, the oral route is the preferred choice for Lomitapide and Epeleuton, with the need to maintain patient convenience and compliance.

Even so, the segment will grow at a CAGR of 11.3% because newer oral products can't compete with how well advanced injectables work. Notwithstanding this, attempts to improve oral bioavailability and patient compliance could underpin steady demand.

By Distribution Channel

Hospital pharmacies continue to be the leading distribution channel, fuelled by the delivery of high-cost biologics and physician-supervised treatments. Hospital pharmacies are expected to grow at a compound annual growth rate (CAGR) of 14.9% from 2025 to 2035. This is because more people will be hospitalised and pay for their medicines, which will help the market. Retail pharmacies are increasing gradually, providing convenience for oral drugs and repeat prescriptions.

The expansion of treatment guidelines for lipid disorders is driving the growth of retail pharmacies at a CAGR of 12.5%. However, expanding digital healthcare consumption and direct-to-patient strategies are driving the fastest growth in the online pharmacy segment.

The market for online pharmacies is expected to grow at a compound annual growth rate (CAGR) of 16.5%. This is because more people are getting online, telemedicine is becoming more common, and people want home delivery.

Competitive Landscape

The big players in the market for treating severe hypertriglyceridemia (SHTG) are competing on price, new biologics, partnerships, and the number of places they can reach. Companies are significantly investing in RNA therapies and FGF21 analogues, and Olezarsen and Pegozafermin are fuelling competition.

Price strategies prioritise premium biologics over affordable oral drugs, ensuring accessibility while maintaining profitability. Players are making alliances with contract manufacturers and research centres to hasten drug development.

Companies are getting regulatory approval and setting up regional distribution networks in order to grow in emerging markets. Mergers and acquisitions are also mounting as companies integrate expertise to cement market leadership.

Industry Share Analysis

Amarin Corporation

• Share: ~30-35%
• Vascepa (icosapent ethyl), Amarin's flagship product, continues to lead the market thanks to its strategy of expanding its cardiovascular risk reduction label and direct-to-physician marketing.

Ionis Pharmaceuticals & Akcea Therapeutics

• Share: ~20-25%
• Ionis's subsidiary Akcea sells Waylivra (volanesorsen) to people with familial chylomicronemia syndrome (FCS) in a specific SHTG group. The company is working on its antisense RNA technology for targeted therapies.

Novo Nordisk

• Share: ~15-20%
• Novo Nordisk is developing its lipid management pipeline, which includes Wegovy (semaglutide) for the treatment of metabolic syndrome-associated hypertriglyceridemia. The company is dedicating itself to conducting real-world evidence studies to strengthen its position.

HLS Therapeutics

• Share: ~10-15%
• HLS distributes Vascepa in Canada and is planning expansions of formulary access. The company is evaluating combination treatments for improved therapeutic effects.

Other Companies (Kowa Pharmaceuticals, Mochida Pharmaceutical, etc.)

• Share: ~10-15% Total
• Each company specialises in the fibrates and derivatives of omega-3. These companies use a regional strategy to operate within Japan and Europe.

Key Developments in 2024

• Amarin Corporation got Vascepa a longer reimbursement plan in Europe, which strengthened its position in key markets like Germany and France. Amarin also launched a Phase IV study to confirm real-world cardiovascular effects.
• Novo Nordisk got positive early results from a study in Ukraine that included obese people with high triglycerides. This made the drug a two-in-one treatment. The company is working with payers to enhance coverage.
• Ionis Pharmaceuticals announced that IONIS-APOCIII-LRx, a new antisense therapy candidate, is moving into mid-stage trials for its use in severe hypertriglyceridemia. The company hopes that this treatment will work better than Waylivra.
• HLS Therapeutics experienced pricing pressure in Canada but responded with patient support programs to enhance adherence. Kowa Pharmaceuticals, in turn, launched a fresh omega-3 product in Japan for moderate to severe SHTG indications.

Key Players

• Ionis Pharmaceuticals
• 89bio, Inc.
• Arrowhead Pharmaceuticals, Inc.
• NorthSea Therapeutics B.V.
• Amryt Pharma
• Afimmune Pharmaceutical
• Zucara Therapeutics
• Novo Nordisk
• Adocia
• Pfizer Inc.
• Sanofi S.A.
• Regeneron Pharmaceuticals, Inc.
• AstraZeneca plc

SHTG Treatment Industry Analysis by Drug Class, Route of Administration, and End User

By Drug Class:

The industry is segmented into olezarsen, pegozafermin, epeleuton and lomitapide

By Drug Delivery Method:

It is segmented into oral route and injectable route

By Distribution Channel:

It is fragmented among hospital pharmacy, retail pharmacy and online pharmacy

By Region:

The industry is studied across North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa